September 21, 2020 -- Integral Molecular was awarded over $520,000 from the state of Pennsylvania to leverage its technologies in COVID-19 research. The grant will enable the company and its partners to develop therapies and vaccines against SARS-CoV-2.
Four of Integral Molecular's technology platforms are being used in the fight against the virus, including:
- MPS Antibody Discovery platform to generate reactive antibodies against SARS-CoV-2 and other coronaviruses
- SARS-CoV-2 reporter virus particles (RVPs) to test the safety for neutralizing immune responses in patients and vaccines
- Membrane protein array (MPA) to rapidly screen for specificity of antibodies for SARS-CoV-2
- Shotgun mutagenesis epitope mapping to optimize vaccine and antibody design
The funding was received through the state's COVID-19 Vaccines, Treatments, and Therapies (CV-VTT) program.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
